Teresa Lopes

Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells

Helicobacter pylori infection is the main risk factor for intestinal metaplasia (IM) and gastric cancer development. IM is a pre-neoplastic lesion, induced by the transcription factor CDX2, where the gastric mucosa is converted to an intestinal phenotype. We previously demonstrated that key elements of the bone morphogenetic protein (BMP) pathway co-localize with CDX2 in IM and upregulate CDX2 expression in gastric cell lines. These observations, together with the hypothesis that CDX2 could be repressed by SOX2, led us to test whether H. pylori, through BMPs, SOX2 and CDX2 could participate in a molecular network critical for the development of IM. AGS cells with and without SMAD4 knock-down were co-cultured with H. pylori or BMP2 to assess the expression of BMP pathway members as well as CDX2 and SOX2 by qPCR and western blot. Proximity ligation assay (PLA) was also performed to evaluate SMAD proteins interaction. Immunohistochemistry and western blot were performed in gastric samples from mice infected with Helicobacter spp. to measure Smad4, pSmad1/5/8, Cdx2 and Sox2 expression in vivo. Increased expression and activity of the BMP pathway accompanied by CDX2 upregulation and SOX2 downregulation were observed in AGS cells co-cultured with H. pylori or BMP2. These effects were impaired by downregulation of the BMP pathway. Finally, infected mice present BMP pathway upregulation, focal Cdx2 expression and decreased Sox2. These results provide a novel link between H. pylori infection and the BMP pathway in the regulation of intestinal and gastric-specific genes that might be relevant for gastric IM.

Curcumin Inhibits Gastric Inflammation Induced by Helicobacter Pylori Infection in a Mouse Model

Helicobacter pylori (H. pylori) infection triggers a sequence of gastric alterations starting with an inflammation of the gastric mucosa that, in some cases, evolves to gastric cancer. Efficient vaccination has not been achieved, thus it is essential to find alternative therapies, particularly in the nutritional field. The current study evaluated whether curcumin could attenuate inflammation of the gastric mucosa due to H. pylori infection. Twenty-eight C57BL/6 mice, were inoculated with the H. pylori SS1 strain; ten non-infected mice were used as controls. H. pylori infection in live mice was followed-up using a modified 13C-Urea Breath Test (13C-UBT) and quantitative real-time polymerase chain reaction (PCR). Histologically confirmed, gastritis was observed in 42% of infected non-treated mice at both 6 and 18 weeks post-infection. These mice showed an up-regulation of the expression of inflammatory cytokines and chemokines, as well as of toll-like receptors (TLRs) and MyD88, at both time points. Treatment with curcumin decreased the expression of all these mediators. No inflammation was observed by histology in this group. Curcumin treatment exerted a significant anti-inflammatory effect in H. pylori-infected mucosa, pointing to the promising role of a nutritional approach in the prevention of H. pylori induced deleterious inflammation while the eradication or prevention of colonization by effective vaccine is not available.

Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H. pylori virulence factors in a paediatric population.

Objective. Serum pepsinogens and gastrin have been proposed as markers of gastritis, but have seldom been studied in children. In this study the aim was to identify host- and Helicobacter pylori-related factors linked to variations in serum gastrin, PGI, PGII, and to evaluate the potential of these biomarkers for diagnosing gastritis, whether H. pylori-associated or not. Material and methods. Ninety-two dyspeptic children referred for endoscopy (peptic ulcer exclusion) were included in the study. H. pylori status (urease, culture, histology) was assessed, and genotype determined (PCR) in H. pylori-positive subjects. Serum gastrin, PGI and PGII levels were measured by standard radioimmunoassay (RIA). Results. PGI and PGII levels were significantly higher in H. pylori-positive subjects (p=0.007; p=0.012, respectively). Gastrin levels were significantly higher in H. pylori-negative subjects (p=0.035). PGI and PGII were associated significantly with higher antrum inflammation scores (p=0.002; p=0.016, respectively); only PGI was associated with age, after controlling for inflammation (p=0.033) and for activity (p=0.037). The contribution of virulence factors could not be assessed owing to the low number of virulent strains. After multivariate analysis, only antrum inflammation was independently associated with PGI level (p=0.012). Receiver operating characteristic (ROC) analysis showed a low PGI and PGII discriminant power for predicting antrum inflammation. Conclusions. Pepsinogen levels as measured in this study seem predominantly to reflect antral inflammation, but they are not an effective screening test for gastritis (H. pylori-positive or -negative) in dyspeptic children.

Role of 13C-Urea Breath Test in Experimental Model of Helicobacter pylori Infection in Mice

Background:  Animal models have been widely used to study Helicobacter pylori infection. Evaluation of H. pylori infection status following experimental inoculation of mice usually requires euthanasia. The 13C‐urea breath test (13C‐UBT) is both sensitive and specific for detection of H. pylori in humans. Thus, it would be very useful to have such a test with the same accuracy for the follow‐up of this infection in animal models of gastric infection. Accordingly, the purpose of this study was to develop and evaluate a 13C‐UBT method for following the course of H. pylori infection in a mouse model.

SELENIUM IN DYSPHAGIC PATIENTS WHO UNDERWENT ENDOSCOPIC GASTROSTOMY FOR LONG TERM ENTERAL FEEDING.

BACKGROUND AND AIMS endoscopic gastrostomy (PEG) patients usually present protein-energy malnutrition, but little is known about selenium deficiency. We aimed to assess serum selenium evolution when patients underwent PEG, after 4 and 12 weeks. We also evaluated the evolution of albumin, transferrin and Body Mass Index and the influence of the nature of the underlying disease. METHODS a blood sample was obtained before PEG (T0), after 4 (T1) and 12 (T3) weeks. Selenium was assayed using GFAAS (Furnace Atomic Absorption Spectroscopy). The PEG patients were fed through homemade meals. Patients were studied as a whole and divided into two groups: head and neck cancer (HNC) and neurological dysphagia (ND). RESULTS we assessed 146 patients (89 males), between 21-95 years old: HNC-56; ND-90. Normal values of selenium in 79% (n=115); low albumin in 77, low transferrin in 94, low values for both serum proteins in 66. Low BMI in 78. Selenium has slow evolution, with most patients still displaying normal Selenium at T3 (82%). Serum protein levels increase from T0 to T3, most patients reaching normal values. The nature of the underlying disease is associated with serum proteins but not with selenium. CONCLUSIONS low serum selenium is uncommon when PEG is performed, after 4 and 12 weeks of enteral feeding and cannot be related with serum proteins levels or dysphagia cause. Enteral nutrition using customized homemade kitchen meals is satisfactory to prevent or correct Selenium deficiency in the majority of PEG patients.

Helicobacter pylori infection: the role of intestinal

no.: WS1.1 HELICOBACTER PYLORI INFECTION AND MARKERS OF GASTRIC CANCER RISK IN ALASKA NATIVE PEOPLE J. Keck,* K. Miernyk,* L. Bulkow,* J. Kelly, B. McMahon, F. Sacco, T. Hennessy* and M. G. Bruce* *Centers for Disease Control and Prevention, Anchorage, AK, USA; Alaska Native Tribal Health Consortium, Anchorage, AK, USA Background: Alaska Native gastric cancer incidence and mortality rates are 3 to 4-times higher than general US population rates. We evaluated pepsinogen I, pepsinogen I/II ratio, anti-H. pylori and CagA antibodies, and blood group to determine their association with gastric cancer development in Alaska Native people. Methods: We conducted a retrospective case-control study that matched gastric cancers reported to the Alaska Native Tumor Registry from 1969–2008 to three controls on known demographic risk factors for H. pylori infection, using previously collected sera from the Alaska Area Specimen Bank. Conditional logistic regression evaluated the associations between serum markers and gastric cancer. Results: We included 122 gastric cancer cases with sera predating cancer diagnosis (mean = 13 years) and 346 matched controls. One hundred and twelve cases (91.8%) and 285 controls (82.4%) had evidence of previous or ongoing H. pylori infection as measured by anti-H. pylori antibodies. Gastric cancer cases had 2.63-fold increased odds of positive anti-H. pylori antibodies compared with their matched controls (p = .01). In a multivariate model, non-cardia gastric cancer (n = 94) was associated with anti-H. pylori antibodies (adjusted OR 3.92, p = .004) and low pepsinogen I (aOR 6.04, p = .04). We found no association between gastric cancer and blood group, anti-CagA antibodies, or pepsinogen I/II ratio. Conclusions: Alaska Native people with gastric cancer had increased odds of previous H. pylori infection. Low pepsinogen I might function as a pre-cancer marker for non-cardia cancer. Impact: Future research to identify Alaska Native individuals with increased gastric cancer risk includes H. pylori genotype and host characteristic studies. Abstract no.: WS1.2 CLUSTERING OF HELICOBACTER PYLORI STRAINS FROM GASTRIC CANCER C. Wang, S. Zhan and Q. Dong Qingdao Municipal Hospital, Qingdao City, Chinano.: WS1.2 CLUSTERING OF HELICOBACTER PYLORI STRAINS FROM GASTRIC CANCER C. Wang, S. Zhan and Q. Dong Qingdao Municipal Hospital, Qingdao City, China Genetic differences between strains play an important role in the determination of clinical outcomes of Helicobacter pylori infection. This study aimed to determine the sequencing types of H. pylori strains from gastric cancer. Materials and Methods: Twenty-two strains of H. pylori were enrolled, including 12 strains from patients with gastric cancer. MLST was used to determine the sequencing type. Results: The seven genetic loci of H. pylori were PCR amplified and sequenced. Those sequences of the seven genes were concatenated, and aligned with the sequences of strains from Europe (5), Africa (5), Asia (5) and other parts of China (16) extracted from the MLST database. A neighbour-joining tree with a kimura 2-parameter model was subsequently constructed. The results showed that all 22 strains, as well as Asia strains from database fell into the HpEastAsia haplogroup which could divided into two groups, groups I and II. Group I consisted of seven cancer strains but only one non-cancer strain of H. pylori, in addition to five strains form database. Fisher’s exact test revealed a statistically significant difference (p = .027). Discussion and Conclusion: The clustering of cancer strains of H. pylori is consistent with a recent report showing that the phylogeopraphic origin of H. pylori is a determinant of gastric cancer risk. This may reflect the consequence of long-term interaction of the bacterium with individual hosts of different genetic ground. The results suggested that the sequencing types could possibly be used to predict the clinical outcomes of H. pylori infection. Abstract no.: WS1.3 LACK OF ASSOCIATION BETWEEN GENE POLYMORPHISMS OF ANGIOTENSIN CONVERTING ENZYME, NOD-LIKE RECEPTOR 1, TOLL-LIKE RECEPTOR 4 AND FAS/FASL WITH THE PRESENCE OF HELICOBACTER PYLORI-INDUCED PREMALIGNANT GASTRIC LESIONS AND GASTRIC CANCER IN CAUCASIANS J. Kupcinskas,* T. Wex, J. Bornschein, M. Selgrad, M. Leja, L. Jonaitis* and P. Malfertheiner *Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Clinic of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany; Faculty of Medicine, University of Latvia, Digestive Diseases Center, Hospital Lizeners, Riga, Latvia Background: Several polymorphisms of genes involved in the immunological recognition of Helicobacter pylori and regulating apoptosis and proliferation have been linked to gastric carcinogenesis, however reported data are partially conflicting. The aim of our study was to evaluate potential associations between the presence of gastric cancer (GC) and high risk atrophic gastritis (HRAG) and polymorphisms of genes encoding Angiotensin converting enzyme (ACE), Nod-like receptor 1 (NOD1), Toll-like receptor 4 (TLR4) and FAS/FASL. Methods: Gene polymorphisms were analyzed in 574 subjects (GC: n = 114; HRAG: n = 222, controls: n = 238) of Caucasian origin. ACE I/D (rs4646994), NOD1 796G>A (rs5743336), TLR4 3725G>C (rs11536889), FAS 1377G>A (rs2234767), FAS 670A>G (rs1800682) and FASL 844T>C (rs763110) were genotyped by different PCR approaches and RFLP analysis. Results: Frequencies of genotypes in our study are similar to the data reported on subjects of Caucasian ethnicity. There was a tendency for NOD1 796G/G genotype to be associated with increased risk of HRAG (62.4% vs 54.5% in controls, p = .082). FAS 670G/G genotype was more frequent in HRAG when compared to controls, 23.9% and 17.2% respectively, however it failed to reach significance level (p = .077). We did not find any significant associations for all examined polymorphism in relation to GC or HRAG. NOD1 796G>A and TLR4 3725G>C gene polymorphisms were also not linked with Helicobacter pylori seropositivity status. Conclusions: ACE, NOD1, TRL4 and FAS/FASL gene polymorphisms are not linked with gastric carcinogenesis in Caucasians, and therefore they should not be considered as potential biomarkers for identifying individuals with higher risk for GC. Abstract no.: WS1.4 ATROPHIC GASTRITIS BY THE OLGA STAGES AND HELICOBACTER CAGA SEROPOSITIVITY IN GASTRIC CANCER T. Vorobjova,* K. Kull,* H. Saar,* R. Labotkin,* A. Zimmermann and H. Maaroos* *University of Tartu, Tartu, Estonia; University of Bern, Bern, Switzerlandno.: WS1.4 ATROPHIC GASTRITIS BY THE OLGA STAGES AND HELICOBACTER CAGA SEROPOSITIVITY IN GASTRIC CANCER T. Vorobjova,* K. Kull,* H. Saar,* R. Labotkin,* A. Zimmermann and H. Maaroos* *University of Tartu, Tartu, Estonia; University of Bern, Bern, Switzerland Introduction: Operative Link on Gastritis Assessment (OLGA) express extent of gastric atrophy in terms of gastritis staging, which severity should be related to gastric cancer. Aim: To study how the OLGA stages of atrophic gastritis are associated with the morphological type, and Helicobacter pylori CagA positivity in gastric cancer. Patients: Twenty two gastric carcinoma patients (8 male, 14 female; mean age 64 ± 12) were operated on. The intestinal type of carcinoma was diagnosed in 12, diffuse in 8, mixed and indeterminate type in two cases (according to Lauren). Methods: Gastric mucosa samples (altogether up to 15) from the each operation specimen were stained with haematoxylin and eosin. Tissue material was received from the primary tumour and the tumour surrounding antral and corpus mucosa. The stage of atrophy by OLGA was established by combining the extent of histologically scored atrophy with the topography of atrophy. IgG antibodies to H. pylori cell surface proteins and CagA were evaluated using ELISA. Results: Of the 12 patients with intestinal type of gastric cancer eight had OLGA stage III or IV, four had OLGA stage II and nobody had OLGA stage I (p < .05). Five patients with diffuse cancer had OLGA stage I and II, two had III stage and one had IV stage. There was no association of OLGA stage or cancer type with CagA positivity. Conclusion: Gastric cancer patients represented all stages of gastric atrophy from OLGA stage I to OLGA stage IV which was not associated with cancer type and CagA seropositivity. a 2011 Blackwell Publishing Ltd, Helicobacter 16 (Suppl. 1): 77–143 79 WS1 Gastric Cancer

Nutraceuticals: a new therapeutic approach against

no.: WS1.1 HELICOBACTER PYLORI INFECTION AND MARKERS OF GASTRIC CANCER RISK IN ALASKA NATIVE PEOPLE J. Keck,* K. Miernyk,* L. Bulkow,* J. Kelly, B. McMahon, F. Sacco, T. Hennessy* and M. G. Bruce* *Centers for Disease Control and Prevention, Anchorage, AK, USA; Alaska Native Tribal Health Consortium, Anchorage, AK, USA Background: Alaska Native gastric cancer incidence and mortality rates are 3 to 4-times higher than general US population rates. We evaluated pepsinogen I, pepsinogen I/II ratio, anti-H. pylori and CagA antibodies, and blood group to determine their association with gastric cancer development in Alaska Native people. Methods: We conducted a retrospective case-control study that matched gastric cancers reported to the Alaska Native Tumor Registry from 1969–2008 to three controls on known demographic risk factors for H. pylori infection, using previously collected sera from the Alaska Area Specimen Bank. Conditional logistic regression evaluated the associations between serum markers and gastric cancer. Results: We included 122 gastric cancer cases with sera predating cancer diagnosis (mean = 13 years) and 346 matched controls. One hundred and twelve cases (91.8%) and 285 controls (82.4%) had evidence of previous or ongoing H. pylori infection as measured by anti-H. pylori antibodies. Gastric cancer cases had 2.63-fold increased odds of positive anti-H. pylori antibodies compared with their matched controls (p = .01). In a multivariate model, non-cardia gastric cancer (n = 94) was associated with anti-H. pylori antibodies (adjusted OR 3.92, p = .004) and low pepsinogen I (aOR 6.04, p = .04). We found no association between gastric cancer and blood group, anti-CagA antibodies, or pepsinogen I/II ratio. Conclusions: Alaska Native people with gastric cancer had increased odds of previous H. pylori infection. Low pepsinogen I might function as a pre-cancer marker for non-cardia cancer. Impact: Future research to identify Alaska Native individuals with increased gastric cancer risk includes H. pylori genotype and host characteristic studies. Abstract no.: WS1.2 CLUSTERING OF HELICOBACTER PYLORI STRAINS FROM GASTRIC CANCER C. Wang, S. Zhan and Q. Dong Qingdao Municipal Hospital, Qingdao City, Chinano.: WS1.2 CLUSTERING OF HELICOBACTER PYLORI STRAINS FROM GASTRIC CANCER C. Wang, S. Zhan and Q. Dong Qingdao Municipal Hospital, Qingdao City, China Genetic differences between strains play an important role in the determination of clinical outcomes of Helicobacter pylori infection. This study aimed to determine the sequencing types of H. pylori strains from gastric cancer. Materials and Methods: Twenty-two strains of H. pylori were enrolled, including 12 strains from patients with gastric cancer. MLST was used to determine the sequencing type. Results: The seven genetic loci of H. pylori were PCR amplified and sequenced. Those sequences of the seven genes were concatenated, and aligned with the sequences of strains from Europe (5), Africa (5), Asia (5) and other parts of China (16) extracted from the MLST database. A neighbour-joining tree with a kimura 2-parameter model was subsequently constructed. The results showed that all 22 strains, as well as Asia strains from database fell into the HpEastAsia haplogroup which could divided into two groups, groups I and II. Group I consisted of seven cancer strains but only one non-cancer strain of H. pylori, in addition to five strains form database. Fisher’s exact test revealed a statistically significant difference (p = .027). Discussion and Conclusion: The clustering of cancer strains of H. pylori is consistent with a recent report showing that the phylogeopraphic origin of H. pylori is a determinant of gastric cancer risk. This may reflect the consequence of long-term interaction of the bacterium with individual hosts of different genetic ground. The results suggested that the sequencing types could possibly be used to predict the clinical outcomes of H. pylori infection. Abstract no.: WS1.3 LACK OF ASSOCIATION BETWEEN GENE POLYMORPHISMS OF ANGIOTENSIN CONVERTING ENZYME, NOD-LIKE RECEPTOR 1, TOLL-LIKE RECEPTOR 4 AND FAS/FASL WITH THE PRESENCE OF HELICOBACTER PYLORI-INDUCED PREMALIGNANT GASTRIC LESIONS AND GASTRIC CANCER IN CAUCASIANS J. Kupcinskas,* T. Wex, J. Bornschein, M. Selgrad, M. Leja, L. Jonaitis* and P. Malfertheiner *Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Clinic of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany; Faculty of Medicine, University of Latvia, Digestive Diseases Center, Hospital Lizeners, Riga, Latvia Background: Several polymorphisms of genes involved in the immunological recognition of Helicobacter pylori and regulating apoptosis and proliferation have been linked to gastric carcinogenesis, however reported data are partially conflicting. The aim of our study was to evaluate potential associations between the presence of gastric cancer (GC) and high risk atrophic gastritis (HRAG) and polymorphisms of genes encoding Angiotensin converting enzyme (ACE), Nod-like receptor 1 (NOD1), Toll-like receptor 4 (TLR4) and FAS/FASL. Methods: Gene polymorphisms were analyzed in 574 subjects (GC: n = 114; HRAG: n = 222, controls: n = 238) of Caucasian origin. ACE I/D (rs4646994), NOD1 796G>A (rs5743336), TLR4 3725G>C (rs11536889), FAS 1377G>A (rs2234767), FAS 670A>G (rs1800682) and FASL 844T>C (rs763110) were genotyped by different PCR approaches and RFLP analysis. Results: Frequencies of genotypes in our study are similar to the data reported on subjects of Caucasian ethnicity. There was a tendency for NOD1 796G/G genotype to be associated with increased risk of HRAG (62.4% vs 54.5% in controls, p = .082). FAS 670G/G genotype was more frequent in HRAG when compared to controls, 23.9% and 17.2% respectively, however it failed to reach significance level (p = .077). We did not find any significant associations for all examined polymorphism in relation to GC or HRAG. NOD1 796G>A and TLR4 3725G>C gene polymorphisms were also not linked with Helicobacter pylori seropositivity status. Conclusions: ACE, NOD1, TRL4 and FAS/FASL gene polymorphisms are not linked with gastric carcinogenesis in Caucasians, and therefore they should not be considered as potential biomarkers for identifying individuals with higher risk for GC. Abstract no.: WS1.4 ATROPHIC GASTRITIS BY THE OLGA STAGES AND HELICOBACTER CAGA SEROPOSITIVITY IN GASTRIC CANCER T. Vorobjova,* K. Kull,* H. Saar,* R. Labotkin,* A. Zimmermann and H. Maaroos* *University of Tartu, Tartu, Estonia; University of Bern, Bern, Switzerlandno.: WS1.4 ATROPHIC GASTRITIS BY THE OLGA STAGES AND HELICOBACTER CAGA SEROPOSITIVITY IN GASTRIC CANCER T. Vorobjova,* K. Kull,* H. Saar,* R. Labotkin,* A. Zimmermann and H. Maaroos* *University of Tartu, Tartu, Estonia; University of Bern, Bern, Switzerland Introduction: Operative Link on Gastritis Assessment (OLGA) express extent of gastric atrophy in terms of gastritis staging, which severity should be related to gastric cancer. Aim: To study how the OLGA stages of atrophic gastritis are associated with the morphological type, and Helicobacter pylori CagA positivity in gastric cancer. Patients: Twenty two gastric carcinoma patients (8 male, 14 female; mean age 64 ± 12) were operated on. The intestinal type of carcinoma was diagnosed in 12, diffuse in 8, mixed and indeterminate type in two cases (according to Lauren). Methods: Gastric mucosa samples (altogether up to 15) from the each operation specimen were stained with haematoxylin and eosin. Tissue material was received from the primary tumour and the tumour surrounding antral and corpus mucosa. The stage of atrophy by OLGA was established by combining the extent of histologically scored atrophy with the topography of atrophy. IgG antibodies to H. pylori cell surface proteins and CagA were evaluated using ELISA. Results: Of the 12 patients with intestinal type of gastric cancer eight had OLGA stage III or IV, four had OLGA stage II and nobody had OLGA stage I (p < .05). Five patients with diffuse cancer had OLGA stage I and II, two had III stage and one had IV stage. There was no association of OLGA stage or cancer type with CagA positivity. Conclusion: Gastric cancer patients represented all stages of gastric atrophy from OLGA stage I to OLGA stage IV which was not associated with cancer type and CagA seropositivity. a 2011 Blackwell Publishing Ltd, Helicobacter 16 (Suppl. 1): 77–143 79 WS1 Gastric Cancer